Related references
Note: Only part of the references are listed.Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma
Ivelina Spassova et al.
CLINICAL CANCER RESEARCH (2020)
Pembrolizumab as first line treatment of Merkel cell carcinoma patients - a case series of patients with various co-morbidities
Tessa Bystrup Boyles et al.
ACTA ONCOLOGICA (2020)
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial
Lisa Zimmer et al.
LANCET (2020)
Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program
John W. Walker et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
Sandra P. D'Angelo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Tumor Ulceration, Reduced Infiltration of CD8-Lymphocytes, High Neutrophil-to-CD8-Lymphocyte Ratio and Absence of MC Virus are Negative Prognostic Markers for Patients with Merkel Cell Carcinoma
Simon Naseri et al.
CANCERS (2020)
FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma
Diana Bradford et al.
ONCOLOGIST (2020)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
Paul Nghiem et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma
Jens von der Gruen et al.
FRONTIERS IN ONCOLOGY (2019)
MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series
Selma Ugurel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - update 2018
Juergen C. Becker et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2019)
Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab
Brooke C. Bloom et al.
FRONTIERS IN ONCOLOGY (2019)
Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series
Jaclyn LoPiccolo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy
Todd C. Knepper et al.
CLINICAL CANCER RESEARCH (2019)
Viral and tumor antigen-specific CD8 T-cell responses in Merkel cell carcinoma
Mahtab Samimi et al.
CELLULAR IMMUNOLOGY (2019)
Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma
Mahtab Samimi
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)
Combined radio-immunotherapy leads to complete clinical regression of stage IV Merkel cell carcinoma
Daniel R. Principe et al.
BMJ CASE REPORTS (2019)
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
Caroline Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics
Kelly G. Paulson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Merkel Cell Carcinoma, Version 1.2018 Clinical Practice Guidelines in Oncology
Christopher K. Bichakjian et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series
Melody J. Xu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥ 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
Howard L. Kaufman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study
Jurgen C. Becker et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372
Shailender Bhatia et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
K. G. Paulson et al.
NATURE COMMUNICATIONS (2018)
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
Nicolas A. Giraldo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy
Natalie J. Miller et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Does Neutron Radiation Therapy Potentiate an Immune Response to Merkel Cell Carcinoma?
Stephanie K. Schaub et al.
INTERNATIONAL JOURNAL OF PARTICLE THERAPY (2018)
Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study
Kelly G. Paulson et al.
CANCER (2017)
Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma
Paul Nghiem et al.
FUTURE ONCOLOGY (2017)
Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA
C. Lance Cowey et al.
FUTURE ONCOLOGY (2017)
Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials
Manni Wang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe
Juergen C. Becker et al.
ONCOTARGET (2017)
Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC)
Suzanne L. Topalian et al.
CANCER RESEARCH (2017)
Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy
Gerald Goh et al.
ONCOTARGET (2016)
Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System
Kelly L. Harms et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma
M. Samimi et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma
Laurence Feldmeyer et al.
CLINICAL CANCER RESEARCH (2016)
Complete spontaneous regression of Merkel cell carcinoma (1986-2016): a 30 year perspective
Noreen M. Walsh
JOURNAL OF CUTANEOUS PATHOLOGY (2016)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma
Jayasri G. Iyer et al.
CANCER MEDICINE (2016)
Neuroendocrine Merkel cell nodal carcinoma of unknown primary site: Management and outcomes of a rare entity
E. A. Kotteas et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline
Celeste Lebbe et al.
EUROPEAN JOURNAL OF CANCER (2015)
Risk of Merkel Cell Carcinoma After Solid Organ Transplantation
Christina A. Clarke et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Risk of Merkel Cell Carcinoma After Solid Organ Transplantation
Christina A. Clarke et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
CD8+ Lymphocyte Intratumoral Infiltration as a Stage-Independent Predictor of Merkel Cell Carcinoma Survival A Population-Based Study
Kelly G. Paulson et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2014)
T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors
Rikke Lyngaa et al.
CLINICAL CANCER RESEARCH (2014)
A better prognosis for Merkel cell carcinoma of unknown primary origin
Kathryn T. Chen et al.
AMERICAN JOURNAL OF SURGERY (2013)
Merkel Polyomavirus-Specific T Cells Fluctuate with Merkel Cell Carcinoma Burden and Express Therapeutically Targetable PD-1 and Tim-3 Exhaustion Markers
Olga K. Afanasiev et al.
CLINICAL CANCER RESEARCH (2013)
Systemic Immune Suppression Predicts Diminished Merkel Cell Carcinoma-Specific Survival Independent of Stage
Kelly G. Paulson et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Tumor-Specific T Cells in Human Merkel Cell Carcinomas: A Possible Role for Tregs and T-Cell Exhaustion in Reducing T-Cell Responses
Mitra Dowlatshahi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Unknown primary Merkel cell carcinoma: 23 new cases and a review
Tina I. Tarantola et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
Tumor Infiltrating Immune Cells and Outcome of Merkel Cell Carcinoma: A Population-Based Study
Harri Sihto et al.
CLINICAL CANCER RESEARCH (2012)
Merkel cell carcinoma: The prognostic implications of an occult primary in stage IIIB (nodal) disease
Matthew Foote et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Merkel Cell Polyomavirus-Specific CD8+ and CD4+ T-cell Responses Identified in Merkel Cell Carcinomas and Blood
Jayasri G. Iyer et al.
CLINICAL CANCER RESEARCH (2011)
Transcriptome-Wide Studies of Merkel Cell Carcinoma and Validation of Intratumoral CD8+ Lymphocyte Invasion As an Independent Predictor of Survival
Kelly G. Paulson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Skin cancers associated with autoimmune conditions among elderly adults
E. Lanoy et al.
BRITISH JOURNAL OF CANCER (2010)
Antibodies to Merkel Cell Polyomavirus T Antigen Oncoproteins Reflect Tumor Burden in Merkel Cell Carcinoma Patients
Kelly G. Paulson et al.
CANCER RESEARCH (2010)
Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients:: the AEIOU features
Michelle Heath et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Clonal integration of a polyomavirus in human Merkel cell carcinoma
Huichen Feng et al.
SCIENCE (2008)
Merkel cell carcinoma and HIV infection
EA Engels et al.
LANCET (2002)
Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: Case series and review of 204 cases
PTH Tai et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
